Syndax Pharmaceuticals (NASDAQ:SNDX) reported strong Q2 2025 financial results, highlighting significant growth in its commercial portfolio. Revuforj generated $28.6M in net revenue, up 43% from Q1, while Niktimvo achieved $36.2M in net revenue in its first full quarter, contributing $9.4M in collaboration revenue to Syndax.
Key developments include FDA Priority Review for Revuforj's sNDA in R/R mNPM1 AML with a PDUFA date of October 25, 2025. The company maintains a strong financial position with $517.9M in cash and expects to reach profitability with stable operating expenses. Clinical data showed promising results, including a 48% overall response rate in R/R mNPM1 AML patients.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.